South Korean lawmaker backs hops-derived CBD at National Assembly forum

A National Assembly forum in Seoul highlighted hops-derived cannabidiol as a cannabis-free alternative with potential regulatory and commercial advantages for Korea’s bio-industry. Member Moon Jin-seok and scientist Dr. Bomi Joseph framed the category as a science-based path forward if safety and sourcing can be verified.

Why it matters: - Member Moon Jin-seok’s endorsement gives hops-derived CBD a public-policy opening in South Korea’s National Assembly. - The forum framed cannabis-free CBD as a possible way to expand the bio-industry without the regulatory baggage tied to THC. - Speakers linked the category to food, cosmetics, healthcare, and pet healthcare markets. - The discussion also positioned Korea to compete in a global market if the sector can clear safety and compliance hurdles.

What happened: - Member Moon Jin-seok delivered the keynote at a forum in the National Assembly Members’ Hall in Seoul. - The event was titled “Opening the Era of Cannabis-Free CBD: A Forum on Fostering the Hops-Derived Bio-Industry.” - The forum focused on CBD sourced from Kriya® brand hops, a non-cannabis plant. - Representatives from Korea’s food science, bio, healthcare, cosmetics, and pet healthcare sectors attended, along with international scientific experts. - Dr. Bomi Joseph delivered the forum’s main scientific presentation.

The details: - Moon said the topic should be handled through responsible public policy and science-based discussion. - Moon said related research and industrial development should improve public health and strengthen Korea’s bio-industry competitiveness. - Moon said he expects the sector could become a future growth industry if it is built on rigorous scientific evidence and independently verified safety. - Moon’s remarks signaled legislative interest in treating hops-derived CBD as a separate regulatory and commercial category from cannabis-derived products. - Dr. Joseph said the CBD molecule can be identical in cannabis and hops, but the source plant and THC presence are what matter. - Dr. Joseph said global regulators are concerned about THC contamination in cannabis-derived products, not CBD itself. - Dr. Joseph said hops-derived CBD comes from a non-cannabis plant in which THC does not exist, making it a potential alternative to reduce regulatory friction. - Dr. Joseph said Korea is well positioned because of its bio-industry, food, and cosmetics capabilities. - Dr. Joseph pointed to the global influence of K-Beauty and Korea’s understanding of botanical raw materials as key advantages. - Dr. Joseph compared the opportunity to the rise of Korean cosmetics companies in the global beauty market over the past two decades. - Dr. Joseph said K-Beauty products containing hops-derived CBD would likely draw strong international interest.

Between the lines: - The forum was as much about regulatory framing as it was about science. - By separating CBD from cannabis in policy discussions, speakers tried to reposition the ingredient around plant source, safety, and trade potential. - The pitch also taps into Korea’s export-oriented branding strength, especially in beauty and wellness. - The event suggests supporters want the government to define clear rules before the industry scales.

What's next: - Further policy discussion could determine whether South Korea treats hops-derived CBD differently from cannabis-derived CBD. - The next step for the sector appears to be more scientific validation and safety verification. - Industry interest will likely hinge on whether regulators accept the source-based distinction and how the market responds. - If the policy case advances, companies in food, cosmetics, healthcare, and pet care could pursue new product development.

The bottom line: - South Korea is starting to test whether hops-derived CBD can become a regulated, non-cannabis growth category for its bio-industry.